Search Results
120 results
Your search is now limited to «Clinical Trials» expert search.
Pulmonary Hypertension News 01/21/2019 08:30
In the 24-week Phase 2 MERIT-1 clinical trial (NCT02021292), researchers tested whether 10 mg of Opsumit would be efficacious, safe, and tolerable for patients with inoperable CTEPH.
More from Pulmonary Hypertension News:
GlobeNewswire 01/17/2019 07:00
Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders and is currently advancing programs for type 2 diabetes, Prader-Willi syndrome and liver diseases.
More from GlobeNewswire: 01/15/2019 10:59
Data from this trial will also be used to develop a protocol for a subsequent Phase 2 clinical trial in stroke patients.
More from 01/14/2019 22:01
Key findings of the HERCULES Phase 3 study of Cablivi include: On the primary endpoint, Cablivi significantly reduced the time to platelet count normalization (p=0.01.
More from
Business Wire 01/10/2019 07:00
Phase 3 clinical trials continue to evaluate the safety and efficacy of luspatercept in patients with MDS (the MEDALIST trial) and in patients with beta-thalassemia (the BELIEVE trial.
More from Business Wire: 01/07/2019 10:30
In 2015, a 10-week phase II trial of 220 patients with Alzheimer's disease showed the drug reduced agitation scores by 1 to 2 points over placebo on a 0 (no symptoms) to 12 (daily severe symptoms) scale.
More from
Healio News 01/07/2019 09:33
A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study, Allergan announced in a press release.
More from Healio News:
PR Newswire 01/07/2019 08:30
Ralinepag (APD811) is being evaluated in a Phase 3 program for pulmonary arterial hypertension (PAH.
More from PR Newswire:
Allergan - CEO Blog 01/07/2019 08:03
Results of this second Phase 3 study with an identical design as the first study, showed that the magnitude of IOP-lowering efficacy with Bimatoprost SR is similar to that observed with topical prostaglandin analogues. 01/07/2019 06:21
NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf) cellular medicines, today announced that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure.
More from
Benzinga 01/07/2019 06:00
Mesoblast Chief Executive Dr Silviu Itescu stated: "Completion of recruitment in this Phase 3 trial, the largest cell therapy trial for heart failure, is a key milestone for Mesoblast and has been achieved on plan.
More from Benzinga:
FeedNavigator 12/24/2018 09:20
... in increases in ApoA-I and cholesterol efflux similar to those observed in patients with AMI and normal renal function or stage 2 CKD enrolled in the ApoA-I Event Reducing in Ischemic Syndromes I trial.
More from FeedNavigator: 12/22/2018 03:38
Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD.
More from
FierceMedicalDevices 12/18/2018 07:25
To test whether selatogrel can meet that need, Idorsia initiated two phase 2 trials of the drug.
More from FierceMedicalDevices:
The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS.
More from Middle East North Africa Financial Network (MENAFN):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications